Trial Search Results
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management.
The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance.
The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure.
The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR.
Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR.
Vs. Medical Therapy Alone:
No further revascularization of coronary artery lesions.
All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
Stanford is currently not accepting patients for this trial.
University of British Columbia
- Procedure: Percutaneous Coronary Intervention (PCI)
- Men and women with severe symptomatic aortic valve stenosis defined as: [aortic valve
area ≤ 1.0 cm2 or aortic valve area index ≤ 0.6 cm2/m2] AND [Jet velocity ≥ 4.0 m/s or
mean gradient ≥ 40 mmHg] AND [NYHA Functional Class ≥ 2 OR abnormal exercise test with
severe SOB, abnormal blood pressure response, or arrhythmia]
- Coronary artery disease defined as: (at least 1 coronary artery lesion of ≥70% visual
angiographic diameter stenosis in a native segment that is at least 2.5 mm in diameter
that is not a CTO and is amenable to treatment with percutaneous coronary intervention
- Consensus by the Multidisciplinary Heart Team that the patient is suitable for
elective transfemoral transcatheter aortic valve replacement (TAVR) with a balloon
expandable transcatheter heart valve AND would receive a bypass with an anastomosis
distal to the coronary artery lesion(s) if they were undergoing surgical aortic valve
- Successful TAVR defined as the implantation of a single transcatheter aortic valve
within the past 96 hours with freedom from more than minimal aortic insufficiency,
stroke, or major vascular complications
- PCI already performed within 90 days prior to TAVR or at the same time as the index
transfemoral TAVR procedure
- Planned PCI of coronary artery lesion(s)
- Planned surgical revascularization of coronary artery lesion(s)
- Non-cardiovascular co-morbidity reducing life expectancy to < 5 years
- Any factor precluding 5-year follow-up
- Prior coronary artery bypass grafting surgery or surgical valve replacement
- Severe mitral regurgitation (> 3+)
- Severe left ventricular dysfunction (LVEF < 30%)
- Low coronary takeoff (high risk for coronary obstruction)
- Acute myocardial infarction within 90 days
- Stroke or transient ischemic attack within 90 days
- Renal insufficiency (eGFR < 30 ml/min) and/or renal replacement Rx
- Hemodynamic or respiratory instability
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study